Measurement of Blood Thiamine Metabolites for Alzheimer's Disease Diagnosis

EBioMedicine

Volumn 3, Issue , 2016, Pages 155-162

  Pan, Xiaoli ^a   Fei, Guoqiang ^a   Lu, Jingwen ^a   Jin, Lirong ^a   Pan, Shumei ^a   Chen, Zhichun ^a   Wang, Changpeng ^a   Sang, Shaoming ^a   Liu, Huimin ^a   Hu, Weihong ^b   Zhang, Hua ^b   Wang, Hui ^c   Wang, Zhiliang ^c   Tan, Qiong ^d   Qin, Yan ^d   Zhang, Qunying ^e   Xie, Xueping ^f   Ji, Yong ^g   Cui, Donghong ^b   Gu, Xiaohua ^h   Xu, Jun ^h   Yu, Yuguo ⁱ   Zhong, Chunjiu ^a   more..

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Department of Internal Medicine   (China)

^d SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

^e Shanghai Haiwan Hospital   (China)

^f SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^g Huanhu Hospital   (China)

^h THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

ⁱ FUDAN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Biomarker; Blood; Diagnosis; Thiamine metabolites

Indexed keywords

APOLIPOPROTEIN E; COCARBOXYLASE; CYANOCOBALAMIN; THIAMINE PHOSPHATE; BIOLOGICAL MARKER; THIAMINE;

ACTIVITY OF DAILY LIVING ASSESSMENT; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DSM-IV; FEMALE; FOLIC ACID BLOOD LEVEL; FRONTOTEMPORAL DEMENTIA; GENETIC ANALYSIS; GLUCOSE METABOLISM; HAMILTON DEPRESSION RATING SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ALLELE; BLOOD; GENETICS; GENOTYPE; METABOLISM; METABOLOME; METABOLOMICS; MIDDLE AGED; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIOMARKERS; FEMALE; GENOTYPE; HUMANS; MALE; METABOLOME; METABOLOMICS; MIDDLE AGED; ROC CURVE; SEVERITY OF ILLNESS INDEX; THIAMINE; THIAMINE MONOPHOSPHATE; THIAMINE PYROPHOSPHATE;

EID: 84958947586     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.11.039     Document Type: Article

References (36)

1. Bettendorff L., Mastrogiacomo F., Kish S.J., Grisar T. Thiamine, thiamine phosphates, and their metabolizing enzymes in human brain. J. Neurochem. 1996, 66(1):250-258.
2. Bozic I., Savic D., Laketa D., Bjelobaba I., Milenkovic I., Pekovic S., et al. Benfotiamine attenuates inflammatory response in LPS stimulated BV-2 microglia. PLoS One 2015, 10(2). (Feb. 19).
3. Butterworth R.F., Besnard A.M. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease. Metab. Brain Dis. 1990, 5(4):179-184.
4. Chen Z., Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for therapeutic and diagnostic strategies. Prog. Neurobiol. 2013, 10.1016/j.pneurobio.2013.06.004.
5. Chen K., Langbaum J.B., Fleisher A.S., et al. Alzheimer's disease Neuroimaging Initiative. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's disease Neuroimaging Initiative. NeuroImage 2010, 51(2):654-664.
6. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Neurol. Arch. 2012, 69(1):29-38.
7. Cummings J.L. Biomarkers in Alzheimer's disease drug development. Alzheimers Dementia 2011, 7(3):e13-e44.
8. Gibson G.E., Blass J.P. Thiamine-dependent processes and treatment strategies in neurodegeneration. Antioxid. Redox Signal. 2007, 9(10):1605-1619.
9. Gibson G.E., Sheu K.F., Blass J.P., et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch. Neurol. 1988, 45(8):836-840.
10. Gibson G.E., Hirsch J.A., Cirio R.T., Jordan B.D., Fonzetti P., Elder J. Abnormal thiamine-dependent processes in Alzheimer's disease. Lessons from diabetes. Mol. Cell. Neurosci. 2013, 55:17-25. (Jul.).
11. Gold M., Chen M.F., Johnson K. Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type. Arch. Neurol. 1995, 52(11):1081-1086.
12. Gold M., Hauser R.A., Chen M.F. Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. Metab. Brain Dis. 1998, 13(1):43-53.
13. Héroux M., Raghavendra Rao V.L., Lavoie J., Richardson J.S., Butterworth R.F. Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease. Metab. Brain Dis. 1996, 11(1):81-88.
14. Hölscher C. First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. Alzheimers Dement. 2014, 10:S33-S37.
15. Karuppagounder S.S., Xu H., Shi Q., Chen L.H., Pedrini S., Pechman D., et al. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol. Aging 2009, 30(10):1587-1600.
16. Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004, 292(23):2901-2908.
17. Mastrogiacoma F., Bettendorff L., Grisar T., Kish S.J. Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease. Ann. Neurol. 1996, 39(5):585-591.
18. McKhann G.M., Albert M.S., Grossman M., et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the work group on frontotemporal dementia and Pick's disease. Arch. Neurol. 2001, 58(11):1803-1809. (Nov.).
19. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7(3):263-269.
20. Mosconi L., Pupi A., De Leon M.J. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann. N. Y. Acad. Sci. 2008, 1147:180-195.
21. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 2008, 49:390-398.
22. Palmert M.R., Usiak M., Mayeux R., Raskind M., Tourtellotte W.W., Younkin S.G. Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology 1990, 40(7):1028-1034.
23. Pan X., Gong N., Zhao J., et al. powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 2010, 133(Pt 5):1342-1351.
24. Price J.C., Klunk W.E., Lopresti B.J., et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J. Cereb. Blood Flow Metab. 2005, 25(11):1528-1547.
25. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70:440-448.
26. Reiman E.M., Caselli R.J., Yun L.S., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 1996, 334(12):752-758.
27. Roman G.C., Tatemichi T.K., Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43(2):250-260.
28. Rosenmann H. CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. J. Mol. Neurosci. 2012, 47:1-14.
29. Shaw L.M., Vanderstichele H., Knapik-Czajka M., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65(4):403-413. (Apr.).
30. Small G.W., Mazziotta J.C., Collins M.T., et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995, 273:942-947.
31. The Ronald and Nancy Reagan Research Institute of The Alzheimer's Association and National Institute on Aging Working Group Consensus report of the working group on: "molecular and biochemical markers of Alzheimer's disease". Neurobiol. Aging 1998, 19(2):109-116.
32. Victoroff J., Mack W.J., Lyness S.A., Chui H.C. Multicenter clinicopathological correlation in dementia. Am. J. Psychiatry 1995, 152(10):1476-1484.
33. Vigo-Pelfrey C., Seubert P., Barbour R., et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995, 45(4):788-793.
34. Zhang Q., Yang G., Li W., Fan Z., Sun A., Luo J., et al. Thiamine deficiency increases β-secretase activity and accumulation of β-amyloid peptides. Neurobiol. Aging 2011, 32(1):42-53.
35. Zhao Y., Pan X., Zhao J., Wang Y., Peng Y., Zhong C. Decreased transketolase activity contributes to impaired hippocampal neurogenesis induced by thiamine deficiency. J. Neurochem. 2009, 111(2):537-546.
36. Zhao J., Sun X., Yu Z., Pan X., Gu F., Chen J., et al. Exposure to pyrithiamine increases β-amyloid accumulation, tau hyperphosphorylation, and glycogen synthase kinase-3 activity in the brain. Neurotox. Res. 2011, 19(4):575-583.